Respiratory syncytial virus-parainfluenza virus vaccine
Alternative Names: FRSV-HNPIV-3Latest Information Update: 20 Jul 1998
Price :
$50 *
At a glance
- Originator Pharmacia Corporation; sanofi pasteur
- Class Respiratory syncytial virus vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Parainfluenza virus infections; Respiratory syncytial virus infections
Most Recent Events
- 20 Jul 1998 No-Development-Reported for Parainfluenza virus infections in USA (Unknown route)
- 20 Jul 1998 No-Development-Reported for Respiratory syncytial virus infections in USA (Unknown route)
- 18 Jan 1995 Preclinical development for Parainfluenza virus infections in USA (Unknown route)